3/253/592608959 |
您所在的位置:网站首页 › 3/253/592608959 |
data-id="" iid="">120.36.3.253http://120.36.3.253:8989/notSupported.asp120.36.3.253:8989网页2020年11月17日 · IE Safari® Safari®
发布时间:2024-07-14data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/37148024Biological therapy for severe asthma - Indian perspectives …网页The present review dissects and summarises the available monoclonal antibodies for asthma treatment in India, the perspectives of Indian patients on biological therapy, and the challenges encountered by patients and physicians in this regard. We provide practical suggestions for utilising monoclonal antibodies and deciding on the optimal agent ...
发布时间:2024-07-14data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/15209959Safety and efficacy of oral fexofenadine in children with …网页In the placebo group, 24.4% of subjects reported adverse events compared with 24.1% for fexofenadine HCl 30 mg b.i.d., and 28.4% for all fexofenadine-treated groups. The most common adverse event overall was headache (4.3% placebo; 5.8% fexofenadine HCl 30 mg b.i.d.; and 7.2% any fexofenadine doses).
发布时间:2024-07-14data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/33611685Are Mendelian randomization investigations immune from …网页2021 Mar;36(3):253-257. doi: 10.1007/s10654-021-00726-8. Epub 2021 Feb 21. Authors Stephen Burgess 1 2 , Sonja A Swanson 3 , Jeremy A Labrecque 3 Affiliations 1 MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. [email protected]. 2 Cardiovascular Epidemiology Unit, Department of ...
发布时间:2024-07-14CopyRight 2018-2019 实验室设备网 版权所有 |